G1 Therapeutics, Inc. (GTHX)
After hours:
| Previous close | 3.7700 |
| Open | 3.5200 |
| Bid | 4.1100 x 400 |
| Ask | 4.1500 x 300 |
| Day's range | 3.5200 - 4.2400 |
| 52-week range | 1.0800 - 5.0000 |
| Volume | |
| Avg. volume | 1,183,075 |
| Market cap | 216.019M |
| Beta (5Y monthly) | 1.70 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.50 |
GlobeNewswireG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., May 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 2,100 shares of G1’s common stock and 1,050 restricted stock units (RSUs) to one hired employee under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to the
GuruFocus.comG1 Therapeutics Inc (GTHX) Q1 2024 Earnings: Close Alignment with Analyst Revenue Projections
Insights into Financial Performance and Strategic Initiatives
ZacksG1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of -5.26% and 4.84%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
